Medical Pharmacology: Chapter 33 — Anti-Cancer Drugs Part I: Pharmacology -- Module 6 — Miscellaneous Cytotoxics, Drug Interactions, and Supportive Pharmacology

Chapter 33 — Anti-Cancer Drugs Part I: Pharmacology — Module 6 — Miscellaneous Cytotoxics, Drug Interactions, and Supportive Pharmacology

1. Hydroxyurea inhibits ribonucleotide reductase, but its action is directed at a specific structural feature of the enzyme rather than at the substrate-binding site. Which feature does hydroxyurea target?

A) The allosteric ATP-binding site on the large R1 subunit, locking the enzyme in an inactive conformation
B) The stable tyrosyl free radical in the small R2 subunit, which hydroxyurea quenches to abolish catalysis
C) The dithiol active-site cysteines on R1 that provide reducing equivalents during catalysis
D) The thioredoxin docking surface that resupplies electrons to the enzyme between cycles
E) The diferric iron center that hydroxyurea chelates and removes from the holoenzyme

ANSWER: B

Rationale:

Ribonucleotide reductase is a heterotetramer of two large R1 subunits and two small R2 subunits. The R2 subunit harbors a stable tyrosyl free radical that is essential for initiating catalysis, and hydroxyurea acts as a radical scavenger that quenches this tyrosyl radical, producing an inactive enzyme and halting the reduction of ribonucleoside diphosphates to deoxyribonucleoside diphosphates.

Option A: Option A is incorrect because hydroxyurea does not work through the allosteric ATP/dATP specificity site on R1; that site governs substrate preference, not the radical hydroxyurea destroys.
Option C: Option C is incorrect because the active-site dithiol cysteines participate in the redox chemistry of substrate reduction but are not the moiety hydroxyurea inactivates.
Option D: Option D is incorrect because thioredoxin (and glutaredoxin) regenerate the active-site thiols externally and are not the hydroxyurea target.
Option E: Option E is incorrect because, although the tyrosyl radical is generated and stabilized by the adjacent diferric iron center in R2, hydroxyurea acts by quenching the radical itself rather than by chelating and stripping the iron center out of the holoenzyme.

2. Asparaginase achieves tumor selectivity that is mechanistically distinct from the selectivity of conventional cytotoxics. Which property of susceptible leukemic blasts accounts for this selectivity?

A) Susceptible blasts overexpress asparagine synthetase, which the drug irreversibly inhibits
B) Susceptible blasts import asparaginase preferentially through an upregulated amino-acid transporter
C) Susceptible blasts harbor a mutation that converts asparagine into a cytotoxic metabolite
D) Susceptible blasts express very low asparagine synthetase and therefore depend on extracellular asparagine that the enzyme depletes
E) Susceptible blasts lack the proteasome required to survive the unfolded protein response

ANSWER: D

Rationale:

Asparaginase hydrolyzes circulating L-asparagine, and its selectivity rests on a metabolic vulnerability of the target cell rather than on rapid proliferation. Many acute lymphoblastic leukemia blasts, especially T-cell ALL, express very low levels of asparagine synthetase, the enzyme that synthesizes asparagine de novo, leaving them dependent on an exogenous supply. When circulating asparagine is depleted, these auxotrophic blasts cannot sustain protein synthesis and undergo apoptosis, while normal cells with intact asparagine synthetase are spared.

Option A: Option A inverts the mechanism: susceptible cells have low, not high, asparagine synthetase, and asparaginase depletes substrate rather than inhibiting that enzyme.
Option B: Option B is incorrect because selectivity arises from synthetic deficiency, not from preferential drug uptake.
Option C: Option C is incorrect because asparagine is not converted into a toxic metabolite; the cytotoxic event is amino-acid starvation.
Option E: Option E is incorrect because, although asparagine depletion does trigger endoplasmic reticulum stress and the unfolded protein response, susceptible blasts are not characterized by proteasome loss; the defining lesion is low asparagine synthetase.

3. PEGylation of E. coli asparaginase changes its pharmacokinetic profile substantially compared with the native enzyme. Which statement most precisely describes that change?

A) The plasma half-life is prolonged from roughly 1.2 days for native asparaginase to approximately 5.5 to 7 days for pegaspargase, allowing dosing every 2 to 4 weeks
B) The plasma half-life is shortened, requiring more frequent dosing but reducing immunogenicity
C) The plasma half-life is unchanged, with PEGylation affecting only the catalytic rate
D) The plasma half-life is prolonged to several months, allowing single-dose induction therapy
E) The plasma half-life is prolonged only in patients who have not developed anti-PEG antibodies, with no change otherwise

ANSWER: A

Rationale:

Conjugating polyethylene glycol to E. coli asparaginase shields antigenic epitopes and markedly extends the circulating half-life from approximately 1.2 days for the native enzyme to roughly 5.5 to 7 days for pegaspargase. This permits dosing every 2 to 4 weeks instead of every few days and reduces the formation of neutralizing antibodies, which is why pegaspargase is the standard preparation in current ALL protocols.

Option B: Option B is incorrect because PEGylation lengthens rather than shortens the half-life.
Option C: Option C is incorrect because the principal effect is pharmacokinetic (duration of exposure), not a change in catalytic turnover.
Option D: Option D overstates the magnitude: the half-life extends to days, not months, and asparaginase is given as repeated doses across a treatment phase rather than as a single induction dose.
Option E: Option E is incorrect because the half-life extension is the baseline pharmacokinetic property of the molecule; anti-PEG antibodies can accelerate clearance and contribute to silent inactivation, but they are not a prerequisite for the prolonged half-life.

4. A patient on pegaspargase tolerates infusions without rash, hypotension, or other overt allergic features, yet monitoring reveals inadequate asparagine depletion. Which phenomenon does this pattern define?

A) Anaphylactoid reaction without measurable antibody formation
B) Pancreatitis-induced reduction in enzyme activity
C) Silent inactivation, in which neutralizing antibodies reduce enzyme activity without clinical hypersensitivity
D) Tachyphylaxis from receptor downregulation at the target cell
E) Pseudoallergy from PEG-triggered complement activation

ANSWER: C

Rationale:

Silent inactivation describes the development of neutralizing anti-asparaginase antibodies that diminish or abolish enzyme activity in the absence of any clinical hypersensitivity reaction. Because the patient appears to tolerate therapy, the loss of efficacy is detected only by inadequate asparagine depletion or by therapeutic drug monitoring of trough asparaginase activity, and it warrants switching to an alternative preparation such as Erwinia asparaginase.

Option A: Option A is incorrect because the defining feature here is loss of enzyme activity from neutralizing antibodies, not an anaphylactoid event, and these patients do form antibodies.
Option B: Option B is incorrect because pancreatitis is a toxicity of asparaginase but does not explain antibody-mediated loss of circulating enzyme activity.
Option D: Option D is incorrect because asparaginase acts as a circulating enzyme depleting a substrate, not through a cell-surface receptor that could downregulate to produce tachyphylaxis.
Option E: Option E is incorrect because PEG-related complement activation describes an infusion-reaction mechanism, whereas the scenario specifies absent clinical reactions with inadequate depletion, which is the signature of silent inactivation.

5. Immunomodulatory drugs bound to cereblon recruit specific neo-substrates for ubiquitylation and proteasomal degradation. Which pair of transcription factors are the shared neo-substrates whose loss drives the anti-myeloma and immunostimulatory effects of all IMiDs?

A) IRF4 and MYC
B) NF-kappa-B p65 and p50
C) CK1-alpha and GSPT1
D) PU.1 and CEBPA
E) Ikaros (IKZF1) and Aiolos (IKZF3)

ANSWER: E

Rationale:

When an IMiD binds cereblon, the substrate-recognition specificity of the CRL4-cereblon E3 ligase is altered so that Ikaros (IKZF1) and Aiolos (IKZF3) are recruited as neo-substrates and degraded by the proteasome. Loss of these zinc-finger transcription factors suppresses myeloma cell survival programs and, in regulatory T cells, releases IL-2 production to produce immunostimulation; these two factors are the common degradation targets across thalidomide, lenalidomide, and pomalidomide.

Option A: Option A is incorrect because IRF4 and MYC fall as a downstream consequence of Ikaros/Aiolos degradation rather than being the directly recruited neo-substrates.
Option B: Option B is incorrect because NF-kappa-B subunits are modulated by IMiDs indirectly and are not the cereblon neo-substrates.
Option C: Option C is incorrect because CK1-alpha is an additional lenalidomide-specific neo-substrate rather than a shared one, and GSPT1 is a neo-substrate of certain investigational molecular glues, not the shared IMiD targets.
Option D: Option D is incorrect because PU.1 and CEBPA are myeloid differentiation factors unrelated to the cereblon neo-substrate mechanism.

6. Lenalidomide produces a nearly disease-specific response in lower-risk myelodysplastic syndrome with isolated deletion 5q. Which mechanistic feature best explains this selectivity?

A) Deletion 5q cells overexpress cereblon, amplifying IMiD-mediated degradation of all neo-substrates
B) Lenalidomide additionally recruits CK1-alpha for degradation, and del(5q) cells are haploinsufficient for the CK1-alpha gene, making them selectively vulnerable
C) Deletion 5q cells lack asparagine synthetase, sensitizing them to lenalidomide
D) Lenalidomide inhibits ribonucleotide reductase preferentially in del(5q) progenitors
E) Deletion 5q removes the cereblon locus, forcing the cell to rely on an alternative degradation pathway

ANSWER: B

Rationale:

In addition to the shared Ikaros and Aiolos neo-substrates, lenalidomide directs cereblon to degrade casein kinase 1-alpha (CK1-alpha). The CK1-alpha gene (CSNK1A1) lies within the commonly deleted region of chromosome 5q, so del(5q) clones are haploinsufficient and unusually dependent on their remaining CK1-alpha; drug-induced degradation of that residual protein selectively kills the del(5q) clone, yielding transfusion independence in roughly two-thirds of these patients.

Option A: Option A is incorrect because the selectivity is driven by CK1-alpha haploinsufficiency, not by cereblon overexpression.
Option C: Option C is incorrect because asparagine synthetase status is the basis of asparaginase selectivity in ALL, not of lenalidomide activity in del(5q) MDS.
Option D: Option D is incorrect because ribonucleotide reductase inhibition is the mechanism of hydroxyurea, not lenalidomide.
Option E: Option E is incorrect because the deleted 5q region does not contain the cereblon locus, and lenalidomide requires intact cereblon to function.

7. Among the immunomodulatory drugs, the route of elimination differs in a way that has practical drug-interaction consequences. Which statement correctly contrasts lenalidomide and pomalidomide elimination?

A) Lenalidomide is predominantly renally excreted and does not require CYP metabolism, whereas pomalidomide undergoes extensive CYP1A2 and CYP3A4 metabolism, making it vulnerable to inducers such as cigarette smoke
B) Both drugs are predominantly renally excreted, so neither is affected by enzyme inducers
C) Lenalidomide is extensively metabolized by CYP3A4 while pomalidomide is renally cleared unchanged
D) Both drugs are eliminated chiefly by biliary excretion of unchanged drug
E) Pomalidomide is renally excreted while lenalidomide is metabolized by CYP2D6

ANSWER: A

Rationale:

Lenalidomide is cleared predominantly by the kidney as largely unchanged drug and requires dose adjustment in renal impairment, but it does not depend on cytochrome P450 metabolism, so CYP-based interactions are minimal. Pomalidomide, by contrast, undergoes substantial CYP1A2 and CYP3A4 metabolism, which makes its exposure susceptible to CYP1A2 inducers such as cigarette smoke and carbamazepine.

Option B: Option B is incorrect because pomalidomide is metabolized rather than purely renally cleared and is therefore affected by inducers.
Option C: Option C reverses the two agents.
Option D: Option D is incorrect because neither IMiD is eliminated chiefly by biliary excretion of unchanged drug.
Option E: Option E is incorrect because lenalidomide is renally cleared rather than CYP2D6-metabolized, and pomalidomide is the CYP-metabolized member of the pair.

8. The azole–vincristine interaction is among the most dangerous in oncology and requires preemptive dose modification. Which description most precisely characterizes both the mechanism and the appropriate response?

A) The azole induces CYP3A4, lowering vincristine exposure, so the vincristine dose must be increased
B) The azole displaces vincristine from plasma protein binding, so the infusion rate must be slowed
C) The azole inhibits P-glycoprotein efflux at the blood-brain barrier, so intrathecal dosing is preferred
D) The azole inhibits CYP3A4-mediated vincristine metabolism, raising exposure and the risk of severe neurotoxicity, so vincristine should be dose-reduced or the azole substituted
E) The azole and vincristine form an inactive complex, so an increased vincristine dose restores efficacy

ANSWER: D

Rationale:

Triazole antifungals such as voriconazole and itraconazole are potent CYP3A4 inhibitors, and vincristine is cleared by CYP3A4. Concurrent use slows vincristine metabolism, elevates exposure at standard doses, and can precipitate severe, sometimes fatal neurotoxicity; the appropriate response is to reduce the vincristine dose or substitute a less potent CYP3A4 inhibitor.

Option A: Option A inverts the pharmacology: azoles inhibit rather than induce CYP3A4, and the exposure rises rather than falls.
Option B: Option B is incorrect because the interaction is metabolic, not a protein-binding displacement remedied by a slower infusion.
Option C: Option C is incorrect and dangerous, because vincristine must never be given intrathecally under any circumstance; the interaction also is not explained by blood-brain barrier efflux inhibition.
Option E: Option E is incorrect because no inactive drug complex forms, and raising the vincristine dose in the presence of a CYP3A4 inhibitor would worsen toxicity.

9. A patient stabilized on imatinib begins rifampin for tuberculosis. Which consequence and management response are correct?

A) Imatinib exposure rises sharply, requiring a dose reduction to prevent toxicity
B) Imatinib exposure is unchanged because imatinib is not a CYP3A4 substrate
C) Imatinib exposure falls by roughly 70% through CYP3A4 induction, risking loss of disease control, so the imatinib dose should be increased or a non-inducing antitubercular substituted
D) Rifampin exposure falls, allowing the tuberculosis to progress despite adequate imatinib levels
E) Imatinib exposure falls only modestly because rifampin is a weak inducer with no clinical significance

ANSWER: C

Rationale:

Rifampin is a potent inducer of CYP3A4, the principal enzyme clearing imatinib, and co-administration reduces imatinib area under the curve by approximately 70%, which threatens loss of disease control. Management requires increasing the imatinib dose (for example, toward 800 mg/day) or, preferably, substituting a non-inducing antitubercular regimen.

Option A: Option A inverts the direction of the interaction, because induction lowers rather than raises exposure.
Option B: Option B is incorrect because imatinib is a CYP3A4 substrate and is therefore affected by induction.
Option D: Option D is incorrect because the clinically important effect is reduced imatinib exposure, not reduced rifampin exposure.
Option E: Option E understates the magnitude, because the roughly 70% reduction in imatinib exposure is clinically significant rather than negligible.

10. Paclitaxel is metabolized chiefly by a different cytochrome isoform than most taxanes-associated interactions would suggest, and a lipid-lowering agent produces a clinically significant interaction through that pathway. Which pairing is correct?

A) Paclitaxel is metabolized by CYP2D6, and paroxetine doubles its exposure
B) Paclitaxel is metabolized by CYP3A4, and grapefruit juice halves its exposure
C) Paclitaxel is metabolized by CYP1A2, and ciprofloxacin reduces its exposure
D) Paclitaxel is metabolized by CYP2C9, and fluconazole reduces its exposure
E) Paclitaxel is metabolized primarily by CYP2C8, and gemfibrozil inhibits this pathway, increasing paclitaxel exposure roughly two-fold

ANSWER: E

Rationale:

Paclitaxel is metabolized primarily by CYP2C8 (with a secondary CYP3A4 contribution), and the fibrate gemfibrozil is a potent CYP2C8 inhibitor that increases paclitaxel area under the curve by approximately two-fold, so gemfibrozil should be discontinued before paclitaxel when feasible.

Option A: Option A is incorrect because CYP2D6 metabolizes tamoxifen rather than paclitaxel, and paroxetine is the relevant inhibitor in the tamoxifen context.
Option B: Option B is incorrect because, although CYP3A4 contributes secondarily, the primary and clinically targeted pathway for the gemfibrozil interaction is CYP2C8, and a CYP3A4 inhibitor like grapefruit juice would raise rather than halve exposure.
Option C: Option C is incorrect because CYP1A2 is not the primary paclitaxel pathway.
Option D: Option D is incorrect because CYP2C9 is not the principal paclitaxel pathway, and the characterized fibrate interaction operates through CYP2C8.

11. Tamoxifen requires metabolic activation, and an antidepressant choice can compromise its efficacy. Which statement most precisely captures the mechanism?

A) Tamoxifen is active as administered, and paroxetine accelerates its clearance, lowering parent drug levels
B) Tamoxifen is a prodrug activated by CYP2D6 to endoxifen, and paroxetine, a potent CYP2D6 inhibitor, reduces endoxifen formation by roughly 65 to 75%
C) Tamoxifen is activated by CYP3A4 to endoxifen, and paroxetine inhibits that pathway
D) Tamoxifen is activated by CYP2C19, and paroxetine induces that enzyme, increasing endoxifen toxicity
E) Tamoxifen efficacy depends on renal clearance of endoxifen, which paroxetine impairs

ANSWER: B

Rationale:

Tamoxifen is a prodrug whose principal active metabolite, endoxifen, is generated largely through CYP2D6. Paroxetine is among the most potent CYP2D6 inhibitors and reduces endoxifen concentrations by approximately 65 to 75%, potentially compromising adjuvant tamoxifen efficacy, so a CYP2D6-sparing antidepressant such as venlafaxine or escitalopram is preferred.

Option A: Option A is incorrect because tamoxifen depends on metabolic activation rather than being fully active as given, and the concern is reduced endoxifen formation rather than accelerated clearance of parent drug.
Option C: Option C is incorrect because the rate-determining activation step relevant to this interaction is CYP2D6-mediated, not CYP3A4-mediated.
Option D: Option D is incorrect because paroxetine inhibits CYP2D6 rather than inducing CYP2C19, and the result is reduced active metabolite rather than increased toxicity.
Option E: Option E is incorrect because the interaction operates at the level of CYP2D6 activation, not renal clearance of endoxifen.

12. Oxaliplatin produces two mechanistically distinct neuropathy syndromes. Which statement correctly distinguishes them?

A) An acute, cold-triggered syndrome of paresthesias attributed to altered sodium channel kinetics, separate from a cumulative dose-dependent sensory neuropathy resembling taxane neuropathy
B) An acute autonomic dysreflexia followed by a chronic motor neuropathy
C) An acute demyelinating syndrome followed by chronic axonal regeneration
D) An acute, cold-triggered syndrome from dorsal root ganglion apoptosis and a cumulative syndrome from sodium channel loss
E) A single dose-independent syndrome that is identical at every cycle

ANSWER: A

Rationale:

Oxaliplatin causes an acute, cold-triggered sensory syndrome appearing within hours to days of infusion, characterized by paresthesias and dysesthesias of the hands, feet, and perioral region and attributed to cold-induced alteration of sodium channel kinetics in sensory axons; this is distinct from the cumulative, dose-dependent sensory neuropathy that builds over multiple cycles and resembles taxane neuropathy.

Option B: Option B is incorrect because the acute syndrome is sensory and cold-triggered rather than autonomic dysreflexia, and the cumulative syndrome is sensory rather than motor.
Option C: Option C is incorrect because oxaliplatin neurotoxicity is not a demyelinating process.
Option D: Option D misattributes the mechanisms: the acute syndrome reflects sodium channel kinetics rather than dorsal root ganglion apoptosis, and dorsal root ganglion injury underlies the cumulative syndrome rather than sodium channel loss.
Option E: Option E is incorrect because the two syndromes differ in onset and dose dependence rather than being a single invariant phenomenon.

13. The pathomechanism of chemotherapy-induced peripheral neuropathy differs by drug class. Which set of mechanism-to-class assignments is correct?

A) Taxanes injure dorsal root ganglion cell bodies; platinum compounds disrupt axonal transport; bortezomib demyelinates
B) Taxanes form DNA adducts in neurons; platinum compounds stabilize microtubules; bortezomib blocks sodium channels
C) Taxanes inhibit the proteasome in axons; platinum compounds stabilize microtubules; bortezomib damages the ganglion
D) Taxanes disrupt microtubule-based axonal transport; platinum compounds form DNA adducts in dorsal root ganglion neurons; bortezomib inhibits the proteasome in ganglion neurons
E) All three classes act by the same final common pathway of direct demyelination

ANSWER: D

Rationale:

Taxane neuropathy arises from stabilization of microtubules that disrupts microtubule-based axonal transport, producing length-dependent distal axonopathy; platinum neuropathy results from accumulation of platinum in dorsal root ganglion neurons where platinum-DNA adducts trigger apoptosis; and bortezomib neuropathy reflects proteasome inhibition in dorsal root ganglion neurons that impairs protein quality control.

Option A: Option A is incorrect because it scrambles taxane and platinum mechanisms and mischaracterizes bortezomib as demyelinating.
Option B: Option B is incorrect because it assigns DNA-adduct formation to taxanes and microtubule stabilization to platinum, reversing the correct pairing.
Option C: Option C is incorrect because it misassigns proteasome inhibition to taxanes and microtubule stabilization to platinum.
Option E: Option E is incorrect because these classes act through distinct mechanisms rather than a shared demyelinating pathway.

14. A patient has established, painful chemotherapy-induced peripheral neuropathy that persists after completion of treatment. Which pharmacologic intervention is supported by the highest level of randomized evidence and is recommended first?

A) Calcium and magnesium infusions, which prevent cumulative neuropathy when given with each cycle
B) Acetyl-L-carnitine, which has demonstrated consistent symptom reduction in randomized trials
C) Duloxetine, the only agent with Level I randomized evidence for reducing established CIPN pain, started at 30 mg daily and titrated to 60 mg daily
D) Vitamin E supplementation, which has Level I evidence for treating established neuropathic pain
E) Topical lidocaine, which has replaced systemic agents as the evidence-based first-line treatment

ANSWER: C

Rationale:

Duloxetine is the only agent supported by Level I randomized evidence for treating established painful chemotherapy-induced peripheral neuropathy and is recommended as first-line therapy, typically started at 30 mg daily and titrated to 60 mg daily.

Option A: Option A is incorrect because calcium and magnesium infusions were studied as prevention for oxaliplatin neuropathy and failed in a randomized trial, and they are not a treatment for established pain.
Option B: Option B is incorrect because acetyl-L-carnitine has not shown consistent benefit and is not recommended; some data even raise concern for worsening neuropathy.
Option D: Option D is incorrect because vitamin E lacks demonstrated benefit and has no Level I support for treating established CIPN.
Option E: Option E is incorrect because topical lidocaine has weak and inconsistent evidence and has not supplanted duloxetine as first-line treatment.

15. Treatment-related myeloid neoplasms differ systematically by the class of causative agent. Which constellation is characteristic of alkylating agent-related disease?

A) Short latency of 1 to 3 years, de novo acute myeloid leukemia, and a KMT2A rearrangement at 11q23
B) Short latency, balanced translocations, and intermediate prognosis with good response to induction
C) Long latency with rapid spontaneous resolution and a favorable karyotype
D) Latency of several decades, normal cytogenetics, and reliable cure with standard induction
E) Long latency of approximately 5 to 10 years, a preceding myelodysplastic phase, and unbalanced loss of chromosome 5 or 7 material with poor prognosis

ANSWER: E

Rationale:

Alkylating agent-related myeloid neoplasms characteristically present after a long latency of roughly 5 to 10 years, are typically preceded by a myelodysplastic phase, and carry unbalanced cytogenetic losses such as monosomy 5/del(5q) or monosomy 7/del(7q), with a poor prognosis and low complete remission rates.

Option A: Option A describes the contrasting topoisomerase II inhibitor pattern (short latency, de novo AML, KMT2A rearrangement).
Option B: Option B is incorrect because it describes the topoisomerase II inhibitor phenotype, with balanced translocations and a more favorable response to induction.
Option C: Option C is incorrect because these neoplasms do not resolve spontaneously and do not carry a favorable karyotype.
Option D: Option D is incorrect because the latency is years rather than decades, the cytogenetics are abnormal rather than normal, and outcomes with standard induction are poor rather than reliably curative.

16. A patient develops acute myeloid leukemia about two years after etoposide-containing therapy, without a preceding myelodysplastic phase. Which cytogenetic and mechanistic profile is most consistent with topoisomerase II inhibitor-related disease?

A) Monosomy 7 arising after a long myelodysplastic prodrome
B) A balanced KMT2A rearrangement at chromosome 11q23, arising because the drug stabilizes topoisomerase II cleavable complexes at this locus and directly generates the translocation
C) Complex karyotype with del(5q) following a 7-year latency
D) Normal cytogenetics with no identifiable mechanism
E) Trisomy 8 caused by ribonucleotide reductase inhibition

ANSWER: B

Rationale:

Topoisomerase II inhibitor-related leukemia typically presents as de novo acute myeloid leukemia after a short latency of about 1 to 3 years and is marked by a balanced rearrangement of KMT2A at chromosome 11q23; these translocations arise because the drug stabilizes topoisomerase II cleavable complexes at specific loci including the KMT2A breakpoint cluster region, directly generating the fusion.

Option A: Option A is incorrect because monosomy 7 after a long myelodysplastic prodrome describes the alkylating agent pattern.
Option C: Option C is incorrect because it describes the alkylating agent phenotype, with a complex karyotype, del(5q), and prolonged latency.
Option D: Option D is incorrect because a defined mechanism and characteristic cytogenetics exist for this entity rather than normal cytogenetics with no mechanism.
Option E: Option E is incorrect because ribonucleotide reductase inhibition is the mechanism of hydroxyurea and is not the basis of topoisomerase II inhibitor-related leukemia.